63628-60-4

Usage

Uses

Used in Pharmaceutical Research:
2-(aminomethyl)-1,3-thiazole-4-carboxylic acid is used as a research compound for its antimicrobial, antifungal, and anticancer properties. It is being studied for its potential to inhibit certain enzymes and as a building block for the synthesis of various pharmaceutical compounds.
Used in Drug Discovery:
2-(aminomethyl)-1,3-thiazole-4-carboxylic acid is used as a lead compound in drug discovery, with its potential biological activities being explored for the development of new therapeutic agents. Its versatility in chemical modifications allows for the creation of derivatives with improved pharmacological properties.
Used in Antimicrobial Applications:
2-(aminomethyl)-1,3-thiazole-4-carboxylic acid is used as an antimicrobial agent, targeting a range of microorganisms. Its ability to inhibit microbial growth makes it a candidate for the development of new antibiotics and antifungal drugs.
Used in Anticancer Applications:
2-(aminomethyl)-1,3-thiazole-4-carboxylic acid is used as an anticancer agent, with studies focusing on its potential to inhibit cancer cell growth and proliferation. It is being investigated for its role in modulating various oncological signaling pathways, which could lead to the development of novel cancer therapies.
Used in Enzyme Inhibition:
2-(aminomethyl)-1,3-thiazole-4-carboxylic acid is used as an enzyme inhibitor, with its potential to inhibit certain enzymes being explored for therapeutic applications. This could lead to the development of new drugs for the treatment of various diseases where enzyme inhibition is a key therapeutic strategy.
Overall, 2-(aminomethyl)-1,3-thiazole-4-carboxylic acid has shown promise in various biomedical applications and continues to be of interest in scientific research. Its potential in pharmaceutical research and drug discovery makes it a valuable compound for further investigation and development.

Upstream product

• 88219-00-5 ethyl 2-(benzamidomethyl)thiazole-4-carboxylate 
• 71904-80-8 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylic acid 

Downstream Products

• 71904-80-8 2-((tert-butoxycarbonylamino)methyl)thiazole-4-carboxylic acid 
• 96363-18-7 (S)-1-[(S)-2-((S)-2-{[2-(1-{[2-(tert-Butoxycarbonylamino-methyl)-thiazole-4-carbonyl]-amino}-3-carbamoyl-propyl)-thiazole-4-carbonyl]-amino}-3-methyl-butyrylamino)-4-methyl-pentanoyl]-pyrrolidine-2-carboxylic acid 2,4,5-trichloro-phenyl ester 
• 96394-11-5 (S)-1-((S)-2-{(S)-2-[(2-{1-[(2-Aminomethyl-thiazole-4-carbonyl)-amino]-3-carbamoyl-propyl}-thiazole-4-carbonyl)-amino]-3-methyl-butyrylamino}-4-methyl-pentanoyl)-pyrrolidine-2-carboxylic acid 2,4,5-trichloro-phenyl ester; compound with trifluoro-acetic acid 

Relevant academic research and scientific papers

Convergent and Modular Synthesis of Candidate Precolibactins. Structural Revision of Precolibactin A

The colibactins are hybrid polyketide-nonribosomal peptide natural products produced by certain strains of commensal and extraintestinal pathogenic Escherichia coli. The metabolites are encoded by the clb gene cluster as prodrugs termed precolibactins. clb+ E. coli induce DNA double-strand breaks in mammalian cells in vitro and in vivo and are found in 55-67% of colorectal cancer patients, suggesting that mature colibactins could initiate tumorigenesis. However, elucidation of their structures has been an arduous task as the metabolites are obtained in vanishingly small quantities (μg/L) from bacterial cultures and are believed to be unstable. Herein we describe a flexible and convergent synthetic route to prepare advanced precolibactins and derivatives. The synthesis proceeds by late-stage union of two complex precursors (e.g., 28 + 17 → 29a, 90%) followed by a base-induced double dehydrative cascade reaction to form two rings of the targets (e.g., 29a → 30a, 79%). The sequence has provided quantities of advanced candidate precolibactins that exceed those obtained by fermentation, and is envisioned to be readily scaled. These studies have guided a structural revision of the predicted metabolite precolibactin A (from 5a or 5b to 7) and have confirmed the structures of the isolated metabolites precolibactins B (3) and C (6). Synthetic precolibactin C (6) was converted to N-myristoyl-d-asparagine and its corresponding colibactin by colibactin peptidase ClbP. The synthetic strategy outlined herein will facilitate mechanism of action and structure-function studies of these fascinating metabolites, and is envisioned to accommodate the synthesis of additional (pre)colibactins as they are isolated.

DNA ALKYLATION AND CROSS-LINKING AGENTS AS COMPOUNDS AND PAYLOADS FOR TARGETED THERAPIES

The present invention is directed to compounds related to precolibactin, pharmaceutical compositions based upon these compounds and methods of synthesis which are employed to provide intermediates and final compounds, which are principally alkylating agents and anticancer compounds. The chemical synthetic approach disclosed facilitates the synthesis of numerous precolibactin analogs which can be used in the treatment of cancer.

Synthesis of the cyclo- Isomers of Dolastatin 3

An all-L configuration reverse order of peptide bonding possibility for the cell growth inhibitory (PS system) cyclic peptide dolastatin 3 was eliminated by synthesis of thiazole amino acid containing peptide 2.By employing a series (Schema I) of mixed ca